Fig. 2: Enrollment and sub-randomization.
From: Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Diagram representing the number of participants initially screened (n = 142), failed enrollment criteria (n = 48), early withdrawals (n = 3), and eligible participants (n = 90) that were included in the trial and assigned to any of the three vaccination regimens (n = 30, per group) and dose (low n = 10, medium n = 10, high n = 10). A participant that initially was considered eligible and received an IM-IM regimen but subsequently failed study criteria due to SARS-CoV-2 antibody positivity is indicated on the left. A detailed description of enrollment failures can be found in Supplementary Table 3.
